Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?
January 2, 2009
Foley Partners Stephen Maebius, Judith Waltz, David Rosen and Associate Sean Tu authored an article titled “Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?” in the January 2, 2009 issue of BNA’s Pharmaceutical Law & Industry Report.
Reproduced with permission from BNA’s Pharmaceutical Law & Industry Report, by The Bureau of National Affairs, Inc. http://www.bna.com.
Author(s)
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…